Clinical Trials List
2011-03-15 - 2017-12-31
Phase II
Terminated5
ICD-10C61
Malignant neoplasm of prostate
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9185
Malignant neoplasm of prostate
-
Trial Applicant
Johnson & Johnson
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- HONG-JENG YU Division of Hematology & Oncology
- - - Division of Hematology & Oncology
- 戴槐青 Division of Urology
- Chia-Chi Lin Division of Hematology & Oncology
- - - Division of Urology
- - - Division of Radiology
- 劉高郎 Division of Radiology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Tzu-Ping Lin Division of Urology
- Hsiao-Jen Chung Division of Urology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Cheng-Kuang Yang Division of Urology
- Shian-Shiang Wang Division of Urology
- Jian-Ri Li Division of Urology
- Chuan-Shu Chen Division of Urology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Cheng-Lung Hsu Division of Hematology & Oncology
- Rita cheng Division of Hematology & Oncology
- Yung-Chang Lin Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
30 participants
-
Global
80 participants
